Cancer ResearchPfizer Tests BCMA Bispecific Antibody Elranatamab in Relapsed Multiple Myeloma
This Phase 1 clinical trial, sponsored by Pfizer, investigated PF-06863135 — now known as elranatamab — a bispecific antibody that simultaneously targets BCMA on myeloma cells and CD3 on T cells, essentially redirecting the immune system to kill cancer. The trial enrolled patients with relapsed or refractory multiple myeloma who had failed prior treatments. Participants received elranatamab either as a single agent intravenously or subcutaneously, or in combination with dexamethasone or lenalidomide. The primary goal was to identify the maximum tolerated dose and the recommended Phase 2 dose. This early-phase work was foundational, as elranatamab has since advanced through clinical development and received FDA approval in 2023 for heavily pretreated multiple myeloma, representing a significant advance for patients with limited options.
